Gufic Biosciences share news, announcements and annual reports
NSE: GUFICBIOBSE: 509079Pharmaceuticals & BiotechnologySmall Cap
Gufic Biosciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1985 on BSE, Oct 2004 on NSE
Last close ₹423.75up ₹3.30 (0.78%)BSE ₹423.70
Share price at the NSE close on 28 Oct 2026. Previous close ₹420.45.
28 Oct: open ₹420.95, high ₹430.70, low ₹414.15
52-week range of traded prices to 28 Oct 2026
₹268.00Low, 9 Mar 2026₹467.80High, 7 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,249 Cr959th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 57.85
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.39
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.02%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 11.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.58
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,56,95560.7% delivered
Gufic Biosciences board and management
40 filed, newest first.
May 2026
29 May · Management
Aug 2025
13 Aug · Management
13 Aug · Management
Jul 2025
May 2025
Nov 2024
22 Nov · Management
Sep 2024
25 Sep · Management
Aug 2024
Jun 2024
28 Jun · Management
Feb 2023
10 Feb · Management
Jun 2022
28 Jun · Management
Mar 2022
Nov 2020
Sep 2020
14 Sep · Management
Dec 2019
Sep 2019
Aug 2019
13 Aug · Management
13 Aug · Management
Jun 2019
Mar 2019
May 2018
31 May · Management
Feb 2018
13 Feb · Management
Nov 2016
Dec 2015
Nov 2014
14 Nov · Management
Dr. M.G. Dhapalapur, Executive Director of the Company has resigned from the directorship of the Company due to pre-occupation his resignation was duley accepted by the Board in their meeting held on November 13, 2014. and Ms. Hemal Deasi, Non-Independent Director has been appointed as an Additional Director w.e.f. November 13, 2014.
Oct 2014
Aug 2014
19 Aug · Management
In the meeting of Board of Director held on August 14, 2014 Board has considered and approved the appointment of Mr. SantoshKumar Sharma as a Company Secretary of the company who would further act as a Compliance Officer w.e.f. June 17, 2014.
Jul 2014
8 Jul · Management
W.e.f.June 17, 2014 Mr. Santoshkumar Sharma has been appointed as the Company Secretary of the Company in terms of Section 203 of the Companies Act, 2013. Further, Mr. Santoshkumar Sharma will also act as the Compliance Officer.
May 2014
20 May · Management
Mr. Prakash Khulbe, Company Secretary and Compliance Officer of the Company has resigned from the Company with effect from the 20th April 2014.
Aug 2013
13 Aug · Management
Mr. Pankaj Gandhi and Mr. Jagdish Shah appointed as additional directors w.e.f. August 01, 2013
Jan 2008
16 Jan · Management
Mr. Sitesh D. Joshi, Company Secretary and Compliance Officer of the Company has resigned from the Company with effect from January 15, 2008.
Oct 2007
9 Oct · Management
Vide its letter dated October 08, 2007 that : "Dr. M.G. Dhapalapur has been appointed as Director of the Company on the Board of Directors of the Company with effect from 1st August 2007."
Jun 2007
28 Jun · Management
Mr. Vijay Agarwal has tendered his resignation as Director from the Board of Directors of the Company with effect from 25th June 2007